Cargando…
Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
BACKGROUND: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function. METH...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737604/ https://www.ncbi.nlm.nih.gov/pubmed/31511044 http://dx.doi.org/10.1186/s13063-019-3639-2 |
_version_ | 1783450686662377472 |
---|---|
author | Wandrag, L. Brett, S. J. Frost, G. S. To, M. Loubo, E. Alves Jackson, N. C. Umpleby, A. M. Bountziouka, V. Hickson, M. |
author_facet | Wandrag, L. Brett, S. J. Frost, G. S. To, M. Loubo, E. Alves Jackson, N. C. Umpleby, A. M. Bountziouka, V. Hickson, M. |
author_sort | Wandrag, L. |
collection | PubMed |
description | BACKGROUND: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function. METHODS: A randomised feasibility study was performed over six months in intensive care (ICU). Patients received 5 g L-EAA five times per day in addition to standard feed (L-EAA group) or standard feed only (control group) for up to 14 days. C-reactive protein, albumin, IL-6, IL-10, urinary 3-MH, nitrogen balance, protein turnover ([1-13C] leucine infusion), muscle depth change (ultrasound), functional change (Katz and Barthel indices) and muscle strength Medical Research Council (MRC) sum score to assess ICU Acquired Weakness were measured sequentially. RESULTS: Eight patients (9.5% of screened patients) were recruited over six months. L-EAA doses were provided on 91/124 (73%) occasions. Inflammatory and urinary marker data were collected; serial muscle depth measurements were lacking due to short length of stay. Protein turnover studies were performed on five occasions. MRC sum score could not be performed as patients were not able to respond to the screening questions. The Katz and Barthel indices did not change. L-EAA delivery was achievable, but meaningful functional and muscle mass outcome measures require careful consideration in the design of a future randomised controlled trial. CONCLUSION: L-EAA was practical to provide, but we found significant barriers to recruitment and measurement of the chosen outcomes which would need to be addressed in the design of a future, large randomised controlled trial. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN79066838. Registered on 25 July 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3639-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6737604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67376042019-09-16 Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study Wandrag, L. Brett, S. J. Frost, G. S. To, M. Loubo, E. Alves Jackson, N. C. Umpleby, A. M. Bountziouka, V. Hickson, M. Trials Research BACKGROUND: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function. METHODS: A randomised feasibility study was performed over six months in intensive care (ICU). Patients received 5 g L-EAA five times per day in addition to standard feed (L-EAA group) or standard feed only (control group) for up to 14 days. C-reactive protein, albumin, IL-6, IL-10, urinary 3-MH, nitrogen balance, protein turnover ([1-13C] leucine infusion), muscle depth change (ultrasound), functional change (Katz and Barthel indices) and muscle strength Medical Research Council (MRC) sum score to assess ICU Acquired Weakness were measured sequentially. RESULTS: Eight patients (9.5% of screened patients) were recruited over six months. L-EAA doses were provided on 91/124 (73%) occasions. Inflammatory and urinary marker data were collected; serial muscle depth measurements were lacking due to short length of stay. Protein turnover studies were performed on five occasions. MRC sum score could not be performed as patients were not able to respond to the screening questions. The Katz and Barthel indices did not change. L-EAA delivery was achievable, but meaningful functional and muscle mass outcome measures require careful consideration in the design of a future randomised controlled trial. CONCLUSION: L-EAA was practical to provide, but we found significant barriers to recruitment and measurement of the chosen outcomes which would need to be addressed in the design of a future, large randomised controlled trial. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN79066838. Registered on 25 July 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3639-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-11 /pmc/articles/PMC6737604/ /pubmed/31511044 http://dx.doi.org/10.1186/s13063-019-3639-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wandrag, L. Brett, S. J. Frost, G. S. To, M. Loubo, E. Alves Jackson, N. C. Umpleby, A. M. Bountziouka, V. Hickson, M. Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
title | Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
title_full | Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
title_fullStr | Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
title_full_unstemmed | Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
title_short | Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
title_sort | leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737604/ https://www.ncbi.nlm.nih.gov/pubmed/31511044 http://dx.doi.org/10.1186/s13063-019-3639-2 |
work_keys_str_mv | AT wandragl leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT brettsj leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT frostgs leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT tom leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT louboealves leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT jacksonnc leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT umplebyam leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT bountzioukav leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy AT hicksonm leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy |